已收录 268921 条政策
 政策提纲
  • 暂无提纲
Neoadjuvant use of imatinib mesylate for treatment of large rectal GIST: case report
[摘要]

The role of drugs that intervene with the tirosine kinase activity on the c-kit receptors in the treatment of gastrointestinal stromal tumors (GISTs) has been considered very important, mainly in large tumors. We report a case of a male patient, 56 years-old, obese, presenting with feeling of rectal pressure and incomplete evacuation. Work-up revealed a large inferior rectal GIST located in the posterior wall, suspected on MRI and confirmed by immunohistochemical study of a parasacral biopsy guided by tomography. The supposed initial approach was an abdominoperineal resection, since tumor was compressing anal canal and sphincter complex. In order to save the sphincters, we have decided to refer patient to neoadjuvant treatment with imatinib mesylate (Glyvec®). After four months of treatment, a down staging of tumor was observed during rectal exam (about 50%), which was smaller on pelvic RNM. Patient was undergone to total mesorectal excision with manual coloanal anastomosis and protective ileostomy. He presented necrosis of mobilized left colon and underwent to resection, and terminal iliac colostomy. Subsequently, patient refused to undergo through a new coloanal anastomosis and remain with iliac colostomy after ileostomy takedown. In the treatment of unresectable or large rectal GISTs, the use of imantinib should be strongly considered, since that radical surgery is the main approach to reduce the possibility of local recurrence.

[发布日期]  [发布机构] 
[效力级别]  [学科分类] 心脏病和心血管学
[关键词] rectal cancer;colorectal neoplasias;surgery;antineoplasic drugs. [时效性] 
   浏览次数:5      统一登录查看全文      激活码登录查看全文